首页|Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy
Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Heart failure (HF) is a leading cause of disease and death from cardiovascular diseases, with cardiovascular diseases accounting for the highest cases of deaths worldwide. The reality is that the quality-of-life survival for those suffering HF remains poor with 45-60% reported deaths within five years. Furthermore, cardiovascular disease is the foremost cause of mortality and disability in people with type 2 diabetes mellitus (T2DM), with T2DM patients having a two-fold greater risk of developing heart failure. The number of T2DM affected persons only continues to surge as there are more than 400 million adults affected by diabetes and an estimated 64.3 million affected by heart failure globally (1). In order to cater to the demands of modern society, the medical field has continuously improved upon the standards for clinical management and its therapeutic approaches. For this purpose, in this review, we aim to provide an overview of the current updates regarding heart failure, to include both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) and their respective treatments, while also diving further into heart failure and its correlation with diabetes and diabetic cardiomyopathy and their respective therapeutic approaches.
Heart failureHeart failure with reserved ejection fraction (HFrEF)Heart failure with preserved ejection fraction (HFpEF)DiabetesDiabetic cardiomyopathy
Amy Hyein Kim、Jung Eun Jang、Jin Han
展开 >
Department of Physiology, College of Medicine, Cardiovascular and Metabolic Disease Center, Smart
NSTL
